{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia4lyp5u2m5vnlhphn6ylofv5q4x25nsgjpcrgnthlkch4qmdhod4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm5ubz4uvvq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifx3w7l47kubpfmhtpjqlwjrebaw67tcgammtghusg2b5h7utl5km"
    },
    "mimeType": "image/jpeg",
    "size": 336489
  },
  "path": "/news/2026-05-favored-nation-prices-medicare-glp.html",
  "publishedAt": "2026-05-18T17:20:03.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "In November 2025, the White House announced pricing deals with multiple pharmaceutical manufacturers to lower domestic prices for glucagon-like peptide-1 receptor agonist drugs (GLP-1RAs) including Ozempic, Wegovy, Mounjaro, and Zepbound. Those deals are part of a new \"most favored nation\" (MFN) policy that ties the cost of GLP-1RAs in the U.S. to the prices paid in other wealthy countries.",
  "title": "At 'most favored nation' prices, can Medicare break even on GLP-1 drugs?"
}